TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27189323

Group type: EXPERIMENTAL
Intervention: S-1 80 mg/m2 twice daily plus nab-paclitaxel 220 mg/m2 on day 1
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: S-1 80 mg/m2 twice daily plus nab-paclitaxel 260 mg/m2 on day 1
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: S-1 and nab-paclitaxel combination therapy
Number of subjects: 16
Study: 25683266

Group type: EXPERIMENTAL
Intervention: 3 nights of 10 hours sleep extension
Number of subjects: 19

Group type: COMPARATOR
Intervention: Targeted acoustic stimuli
Number of subjects: 19
Study: 23289543

Group type: EXPERIMENTAL
Intervention: Expressive disclosure about their disease
Number of subjects: 48

Group type: COMPARATOR
Intervention: No disclosure (control group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Expressive disclosure (for those low in Ambivalence over Emotional Expression - AEE)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Expressive disclosure (for those high in AEE)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (for those high in AEE)
Number of subjects: 48
Study: 21320109

Group type: EXPERIMENTAL
Intervention: Carisbamate 800 mg/day
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Carisbamate 1,200 mg/day
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Combined carisbamate doses
Number of subjects: 547

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Carisbamate 1,200 mg
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Carisbamate 800 mg
Number of subjects: 547
Study: 19276857

Group type: EXPERIMENTAL
Intervention: 7 g L-arginine before resistance exercise
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo before resistance exercise
Number of subjects: 18
Study: 17093165

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study: 15020659

Group type: EXPERIMENTAL
Intervention: Bicalutamide 80 mg combined with LHRH agonist
Number of subjects: 205

Group type: COMPARATOR
Intervention: LHRH agonist monotherapy
Number of subjects: 205
Study: 11293456

Group type: EXPERIMENTAL
Intervention: Conditions expected to produce positive transfer via dimension differentiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conditions expected to produce positive transfer via selective attention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial and final categorizations sharing relevant or irrelevant dimensions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both irrelevant dimensions becoming relevant and relevant dimensions becoming irrelevant
Number of subjects: 0
Study: 9176019

Group type: EXPERIMENTAL
Intervention: Adrenomedullin (2 ng min‐1 kg‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Adrenomedullin (8 ng min‐1 kg‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 8
Study: 7937815

Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) mapping of the hand sensorimotor area
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 0
Study: 31079973

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 1167

Group type: EXPERIMENTAL
Intervention: Aspirin plus VKA
Number of subjects: 1167

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus VKA
Number of subjects: 1167

Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel plus VKA
Number of subjects: 1167

Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 1167

Group type: EXPERIMENTAL
Intervention: Clopidogrel alone
Number of subjects: 1167

Group type: EXPERIMENTAL
Intervention: No antithrombotic medication
Number of subjects: 1167

Group type: COMPARATOR
Intervention: History of AF
Number of subjects: 1167
Study: 29232592

Group type: EXPERIMENTAL
Intervention: RIF
Number of subjects: 83

Group type: COMPARATOR
Intervention: ATO
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: RIF and ATO
Number of subjects: 83
Study: 26644184

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (AL)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: artesunate-amodiaquine (ASAQ)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine (DHAPQ)
Number of subjects: 393
Study: 24736677

Group type: EXPERIMENTAL
Intervention: B12 Supplement (oral cyanocobalamin 6 μg/day)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: COMPARATOR
Intervention: B12 Dietary Advice
Number of subjects: 62
Study: 22093652

Group type: EXPERIMENTAL
Intervention: Taekwondo training (1 hour per day for three months)
Number of subjects: 44

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 44
Study: 20624510

Group type: EXPERIMENTAL
Intervention: Combined exercise and cognitive behavioral therapy (EX/CBT)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 74
Study: 18923204

Group type: EXPERIMENTAL
Intervention: Re-irradiation with demand dilatation
Number of subjects: 69

Group type: COMPARATOR
Intervention: Per-oral endoscopic dilatation alone
Number of subjects: 69
Study: 15565164

Group type: EXPERIMENTAL
Intervention: All trans retinoic acid (ATRA) and chemotherapy
Number of subjects: 129
Study: 12729868

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control Therapy (intensive occupational therapy activities)
Number of subjects: 33
Study: 10323627

Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block (DPNB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Topical placebo (control)
Number of subjects: 50
Study: 8704751

Group type: EXPERIMENTAL
Intervention: Refresher training program for health personnel in areas A and B
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Community education program in areas A and C
Number of subjects: 1600

Group type: COMPARATOR
Intervention: No intervention in area D
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Combined intervention areas A and B
Number of subjects: 1600
Study: 1672634

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (54 micrograms)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Metaproterenol sulfate (1.95 mg)
Number of subjects: 30
Study: 6216093

Group type: EXPERIMENTAL
Intervention: 2 g mezlocillin three times
Number of subjects: 96

Group type: COMPARATOR
Intervention: 1.5 g cefuroxime three times
Number of subjects: 96
Study: 31557895

Group type: EXPERIMENTAL
Intervention: Self-reported physical activity (PA)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Measured physical activity (PA) using accelerometer
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Children's physical activity (PA) measured using accelerometer
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Children's body composition assessed using TANITA bioelectrical impedance device
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Pre-pregnancy body mass index (BMI) of mothers
Number of subjects: 199
Study: 29480965

Group type: EXPERIMENTAL
Intervention: Intercostal nerve block (ICNB) treatment (Group B)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Sufentanil treatment (Group A)
Number of subjects: 81
Study: 27909127

Group type: EXPERIMENTAL
Intervention: Arthroscopic management
Number of subjects: 273

Group type: COMPARATOR
Intervention: Open management
Number of subjects: 273
Study: 25444576

Group type: EXPERIMENTAL
Intervention: 10 g/day soluble milk proteins rich in leucine (PRO)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise training
Number of subjects: 48
Study: 21718373

Group type: EXPERIMENTAL
Intervention: Resin-based fissure sealant
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional composite resin
Number of subjects: 30
Study: 20194853

Group type: EXPERIMENTAL
Intervention: DTIC+IFN‐alpha+Talpha1 (3.2 mg)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: DTIC+Talpha1 (3.2 mg)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Control group (DTIC+IFN‐alpha)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Talpha1 (any dosage)
Number of subjects: 488
Study: 18629317

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) at 200 microg/m(3)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) at 100 microg/m(3)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 27
Study: 16171841

Group type: EXPERIMENTAL
Intervention: Visual distracter (green) presented with a red target in Experiment 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual distracter (green) presented with a red target in Experiment 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual distracter (green) presented with a red target in Experiment 3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lone distracter (anti-target) presented without a target in Experiment 4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual distracter (green) presented with a red target in Experiments 5 and 6
Number of subjects: 0
Study: 12385067

Group type: EXPERIMENTAL
Intervention: 20 mg of sublingual stabilized NADH (n = 18)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Identical placebo tablets (n = 17)
Number of subjects: 35
Study: 10212076

Group type: EXPERIMENTAL
Intervention: Cisapride (0.2 mg/kg, 8 hourly)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7754011

Group type: EXPERIMENTAL
Intervention: Gd-EOB-DTPA at doses of 10, 25, 50, and 100 mumol/kg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Gd-EOB-DTPA
Number of subjects: 44
Study: 2309538

Group type: EXPERIMENTAL
Intervention: Fentanyl (10 micrograms.kg‐1 loading dose and 2 micrograms.kg‐1 increments)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Alfentanil (100 micrograms.kg‐1 initial loading dose and either 20 micrograms.kg‐1 increments or 1 microgram.kg‐1.min‐1 continuous infusion)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Alfentanil (100 micrograms.kg‐1 initial loading dose)
Number of subjects: 39
Study: 121645

Group type: EXPERIMENTAL
Intervention: diet plus glibenclamide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: diet plus gliclazide
Number of subjects: 10
Study: 30796127

Group type: EXPERIMENTAL
Intervention: Diabetes Community Exercise and Education Programme (DCEP)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 220
Study: 29283913

Group type: EXPERIMENTAL
Intervention: Round Window Approach (RWA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard Cochleostomy Approach (SCA)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups (RWA and SCA)
Number of subjects: 46
Study: 27348907

Group type: EXPERIMENTAL
Intervention: Plum-blossom needle tapping at Jiaji (EX-B 2) combined with rehabilitation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional rehabilitation training
Number of subjects: 60
Study: 25251930

Group type: EXPERIMENTAL
Intervention: Rhodiola crenulata/Cordyceps sinensis supplementation (1400 mg R + 600 mg C per day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Rhodiola crenulata/Cordyceps sinensis supplementation (RC)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups (RC and Placebo)
Number of subjects: 18
Study: 22483761

Group type: EXPERIMENTAL
Intervention: 0.18% sodium hyaluronate solution (0.18% SH)
Number of subjects: 304

Group type: COMPARATOR
Intervention: saline
Number of subjects: 304

Group type: COMPARATOR
Intervention: carbomer
Number of subjects: 304
Study: 20447652

Group type: EXPERIMENTAL
Intervention: Low-dose quetiapine (100-400 mg/day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 33
Study: 18929262

Group type: EXPERIMENTAL
Intervention: Damon3 self-ligating brackets
Number of subjects: 62

Group type: COMPARATOR
Intervention: Synthesis conventionally ligated brackets
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both appliances
Number of subjects: 62
Study: 16083781

Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 microg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ciclesonide 40 microg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 12953283

Group type: EXPERIMENTAL
Intervention: Clustered survival times
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clustered survival time design
Number of subjects: 0
Study: 11096139

Group type: EXPERIMENTAL
Intervention: Systematic reviews of management interventions for ESRD
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Systematic search methodology
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Development of a register of randomized controlled trials (RCTs)
Number of subjects: 12000
Study: 8783319

Group type: EXPERIMENTAL
Intervention: Naloxone (opiate antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proglumide (cholecystokinin antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1450090

Group type: EXPERIMENTAL
Intervention: Flosequinan
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 25
Study: 3893508

Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg orally)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31126574

Group type: EXPERIMENTAL
Intervention: Soy milk (240 ml/day for 8 weeks)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (500-calorie deficit diet without soy milk)
Number of subjects: 66
Study: 28361752

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Modern diet (high in grains, dairy, and sugar; low in vegetables, fish, and poultry)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Traditional diet (reciprocal of Modern)
Number of subjects: 220
Study: 26712220

Group type: EXPERIMENTAL
Intervention: ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: COPP-EBV-CAD (cyclophosphamide, lomustine, vindesine, melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine, and bleomycin)
Number of subjects: 307
Study: 25148829

Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg/day + fenofibrate 200 mg/day
Number of subjects: 42

Group type: COMPARATOR
Intervention: pravastatin 40 mg/day
Number of subjects: 42
Study: 21801104

Group type: EXPERIMENTAL
Intervention: Lidocaine cream (4% lidocaine)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream (2.5%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 19561035

Group type: EXPERIMENTAL
Intervention: Whole body vibration plus exercise three times per week for four weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Exercise alone three times per week for four weeks
Number of subjects: 16
Study: 17468312

Group type: EXPERIMENTAL
Intervention: 4DS instructors
Number of subjects: 95

Group type: COMPARATOR
Intervention: Faculty instructors
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 4DS teaching experience
Number of subjects: 95
Study: 16335883

Group type: COMPARATOR
Intervention: Telmisartan 40 mg plus HCTZ 12.5 mg (T40/H12.5)
Number of subjects: 805

Group type: COMPARATOR
Intervention: Telmisartan 80 mg plus HCTZ 12.5 mg (T80/H12.5)
Number of subjects: 805
Study: 12003701

Group type: EXPERIMENTAL
Intervention: Reserpine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 0
Study: 9865456

Group type: EXPERIMENTAL
Intervention: 10 mg intravenous dose of methylprednisolone (Phase II)
Number of subjects: 12
Study: 7711991

Group type: EXPERIMENTAL
Intervention: sustained-release diltiazem 180 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: sustained-release nicardipine 40 mg
Number of subjects: 20
Study: 2403775

Group type: EXPERIMENTAL
Intervention: Morphine sulfate (30 mg, intramuscularly)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 354483

Group type: EXPERIMENTAL
Intervention: tranexamic acid, 6 gm daily for 14 to 21 days
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional therapy (bedrest, dexamethasone when cerebral edema developed, plus isotonic saline)
Number of subjects: 39
Study: 31360707

Group type: EXPERIMENTAL
Intervention: Group A: Three parallel partial thread screws (PTSs) with intact posteromedial cortex
Number of subjects: 24

Group type: COMPARATOR
Intervention: Group B: Same fixation of cannulated screws (CSs) as group A but with removed posteromedial cortex
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Group C: Two inferior PTSs replaced by two fully thread screws (FTSs)
Number of subjects: 24
Study: 28533108

Group type: EXPERIMENTAL
Intervention: xylazine (1 mg kg−1) and tiletamine–zolazepam (8 mg kg−1) with hyaluronidase (400 IU)
Number of subjects: 6

Group type: COMPARATOR
Intervention: xylazine (1 mg kg−1) and tiletamine–zolazepam (8 mg kg−1) (control treatment, CON)
Number of subjects: 6
Study: 26385029

Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg twice daily
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study: 25110952

Group type: EXPERIMENTAL
Intervention: 6% carbohydrate beverage (CHOb)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo beverage (PLAb)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 6% carbohydrate capsules (CHOc)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo capsules (PLAc)
Number of subjects: 10
Study: 21606323

Group type: EXPERIMENTAL
Intervention: Prime Time intervention (case management services and peer leadership groups)
Number of subjects: 0
Study: 19320804

Group type: EXPERIMENTAL
Intervention: L-arginine supplementation during the first 28 days of life
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 132
Study: 17300625

Group type: COMPARATOR
Intervention: 0 ml of soya milk (0 g of fat)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 ml of soya milk (0.32 g of fat)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 40 ml of soya milk (1.28 g of fat)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 150 ml of soya milk (4.8 g of fat)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 500 ml of soya milk (16 g of fat)
Number of subjects: 12
Study: 15362961

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 11165424

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment regimens
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Closeout visit
Number of subjects: 902
Study: 9848038

Group type: EXPERIMENTAL
Intervention: Thrombospondin-1 (TSP-1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CSVTCG receptor
Number of subjects: 0
Study: 7862786

Group type: EXPERIMENTAL
Intervention: Level-of-care instrument
Number of subjects: 300
Study: 2480239

Group type: EXPERIMENTAL
Intervention: iloprost 6 ng kg‐1 min‐1
Number of subjects: 42

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study: 7351498

Group type: EXPERIMENTAL
Intervention: Eosinophil chemotactic factor (ECF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Activated serum
Number of subjects: 0
Study: 31010873

Group type: EXPERIMENTAL
Intervention: Transition program with a transition coordinator
Number of subjects: 205

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 205
Study: 28100507

Group type: EXPERIMENTAL
Intervention: Iron-supplement bars (14 mg Fe/day) for 90 days
Number of subjects: 361

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 361
Study: 25538166

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 86
Study: 23011357

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) at a dose of 7.5 mg/week over 12-18 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30
Study: 21167689

Group type: EXPERIMENTAL
Intervention: Cognitive enhancement therapy (CET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enriched supportive therapy (EST)
Number of subjects: 0
Study: 20214120

Group type: EXPERIMENTAL
Intervention: Olyset long-lasting insecticide-treated bednets
Number of subjects: 8620

Group type: COMPARATOR
Intervention: Control areas (no bednets)
Number of subjects: 8620
Study: 18577202

Group type: EXPERIMENTAL
Intervention: Time-action analysis (TAA) of the surgical technique
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Goal Oriented Phases (GOP) of the surgical procedure
Number of subjects: 20
Study: 15131077

Group type: EXPERIMENTAL
Intervention: ICSI of MI oocytes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICSI of rescued IVM MII oocytes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICSI of mature MII oocytes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arrested IVM MI oocytes
Number of subjects: 0
Study: 11448476

Group type: EXPERIMENTAL
Intervention: Etretinate (Tigason) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etretinate (Tigason) in vitro
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topically treated psoriatics (control group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 0
Study: 9574374

Group type: COMPARATOR
Intervention: Early elective surgery
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 155
Study: 8368641

Group type: EXPERIMENTAL
Intervention: LTD4 inhalation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PAF inhalation
Number of subjects: 0